Paper37814010
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
Encarnación-Rosado J and 13 others. Nat Cancer, 2024. Cited by 124 papers, by iCite.
Cite this record
ConductScience Library. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Papers, record 37814010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37814010
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pancreatic Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Humans | |
| Glutamine | |
| Cell Line, Tumor | |
| Enzyme Inhibitors |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016087 | NCI NIH HHS | United States | P30CA016087 | PubMed and NIH | NIH RePORTER |
| R35 CA232124 | NCI NIH HHS | United States | R35CA232124 | PubMed and NIH | NIH RePORTER |
| S10 OD021747 | NIH HHS | United States | S10OD021747 | PubMed and NIH | NIH RePORTER |
| R01 CA251726 | NCI NIH HHS | United States | R01CA251726 | PubMed and NIH | NIH RePORTER |
| P01 CA117969 | NCI NIH HHS | United States | P01CA117969 | PubMed and NIH | NIH RePORTER |
| P01A1080192 | National Cancer Institute (NCI) | PubMed | PubMed | ||
| 1R01CA251726-01A1 | NCI NIH HHS | United States | R01CA251726 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Derived from the trial | Yes |
Source ClinicalTrials.gov
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32510550 | Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. | J Exp Med | 2020 | https://conductscience.org/library/papers/32510550 | PubMed |
| 2 | 17872411 | Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. | Science | 2007 | https://conductscience.org/library/papers/17872411 | PubMed |
| 3 | 36383674 | Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. | Sci Adv | 2022 | https://conductscience.org/library/papers/36383674 | PubMed |
| 4 | 36973407 | Nucleotide metabolism: a pan-cancer metabolic dependency. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/36973407 | PubMed |
| 5 | 31221965 | Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. | Nat Commun | 2019 | https://conductscience.org/library/papers/31221965 | PubMed |
| 6 | 35930753 | Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems. | Mol Cancer Ther | 2022 | https://conductscience.org/library/papers/35930753 | PubMed |
| 7 | 32393771 | Pancreatic cancer stroma: an update on therapeutic targeting strategies. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32393771 | PubMed |
| 8 | 16585505 | Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16585505 | PubMed |
| 9 | 22101431 | Reductive carboxylation supports growth in tumour cells with defective mitochondria. | Nature | 2011 | https://conductscience.org/library/papers/22101431 | PubMed |
| 10 | 36949199 | RHOJ controls EMT-associated resistance to chemotherapy. | Nature | 2023 | https://conductscience.org/library/papers/36949199 | PubMed |
| 11 | 31257175 | EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis. | Dev Cell | 2019 | https://conductscience.org/library/papers/31257175 | PubMed |
| 12 | 37059070 | Pancreatic cancer: Advances and challenges. | Cell | 2023 | https://conductscience.org/library/papers/37059070 | PubMed |
| 13 | 34244439 | The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34244439 | PubMed |
| 14 | 33142117 | Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. | Cell | 2020 | https://conductscience.org/library/papers/33142117 | PubMed |
| 15 | 32302552 | Nitrogen Metabolism in Cancer and Immunity. | Trends Cell Biol | 2020 | https://conductscience.org/library/papers/32302552 | PubMed |
| 16 | 34117030 | Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. | Cancer Res | 2021 | https://conductscience.org/library/papers/34117030 | PubMed |
| 17 | 20473272 | The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. | EMBO J | 2010 | https://conductscience.org/library/papers/20473272 | PubMed |
| 18 | 33027658 | Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. | Cell Rep | 2020 | https://conductscience.org/library/papers/33027658 | PubMed |
| 19 | 28671190 | Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. | Nat Commun | 2017 | https://conductscience.org/library/papers/28671190 | PubMed |
| 20 | 22101433 | Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. | Nature | 2011 | https://conductscience.org/library/papers/22101433 | PubMed |
Cited by111
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977746 | Hepatocyte IRE1α-XBP1s axis prevents pro-metastatic niche formation through metabolic rewiring of inflammatory monocytes. | Nat Commun | 2026 | https://conductscience.org/library/papers/42977746 | PubMed |
| 42962039 | Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity. | Sci Adv | 2026 | https://conductscience.org/library/papers/42962039 | PubMed |
| 42914976 | Cell-state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer. | Cell | 2026 | https://conductscience.org/library/papers/42914976 | PubMed |
| 42846986 | Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity. | Fundam Res | 2026 | https://conductscience.org/library/papers/42846986 | PubMed |
| 42834042 | Glutamine metabolism in health and disease. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42834042 | PubMed |
| 42824134 | Glutamine metabolism and its roles in tumor radiotherapy by regulating DNA damage repair. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42824134 | PubMed |
| 42812576 | Glutamine Metabolism in Health and Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42812576 | PubMed |
| 42801687 | High-Density Type I Collagen Promotes IFN-γ+ CD8+ T Cell Exhaustion via SAT1-ASS1-Mediated Glutamine Accumulation and Ferroptosis in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42801687 | PubMed |
| 42778596 | Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. | Nature | 2026 | https://conductscience.org/library/papers/42778596 | PubMed |
| 42757482 | A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer. | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42757482 | PubMed |
| 42729867 | Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression. | Front Oncol | 2026 | https://conductscience.org/library/papers/42729867 | PubMed |
| 42729077 | Multi-omics integration identifies HSPA4 as a therapeutic target and reveals DON-induced endoplasmic reticulum stress in bladder cancer. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42729077 | PubMed |
| 42703620 | KRAS-driven cytokine-metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma. | Front Genet | 2026 | https://conductscience.org/library/papers/42703620 | PubMed |
| 42700331 | Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42700331 | PubMed |
| 42642776 | Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42642776 | PubMed |
| 42602712 | Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. | iScience | 2026 | https://conductscience.org/library/papers/42602712 | PubMed |
| 42565215 | The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting. | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42565215 | PubMed |
| 42561948 | Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42561948 | PubMed |
| 42514928 | 70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514928 | PubMed |
| 42507221 | Rewiring glucose metabolism in pancreatic cancer by natural compounds: implications for immune evasion and therapeutic targets. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42507221 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| ATEZOLIZUMAB | CHEMBL3707227 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3707227 | ChEMBL |
| SIRPIGLENASTAT | CHEMBL4650367 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4650367 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37814010
GET https://conductscience.org/api/papers/v1/37814010/references?page=2